Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma
SuPAR represents a promising novel biomarker in patients with HCC treated with ICI-based therapies and bears the potential to guide the selection of antitumoral systemic therapies in patients with advanced liver cirrhosis.
Authors
- Sven Lamatsch
- Hilmar Berger (ORCID: https://orcid.org/0000-0002-6304-4946)
- Janett Fischer (ORCID: https://orcid.org/0000-0002-8710-101X)
- Kai Kappert (ORCID: https://orcid.org/0000-0001-6976-0428)
- Minh D. Phan (ORCID: https://orcid.org/0000-0002-6132-5277)
- Cornelius Engelmann (ORCID: https://orcid.org/0009-0006-3813-7397)
- Burcin Özdirik (ORCID: https://orcid.org/0000-0002-8885-737X)
- Münevver Demir (ORCID: https://orcid.org/0000-0002-7050-797X)
- Florian van Bömmel (ORCID: https://orcid.org/0000-0003-2679-0672)
- R Tauber (ORCID: https://orcid.org/0000-0002-0687-3940)
- Rhea Veelken
- Fabian Jost‐Brinkmann (ORCID: https://orcid.org/0000-0002-4018-9720)
- Tobias Puengel (ORCID: https://orcid.org/0000-0003-2662-6127)
- Frank Tacke (ORCID: https://orcid.org/0000-0001-6206-0226)
- Raphael Mohr (ORCID: https://orcid.org/0000-0003-2403-4275)
- Jana Knorr‐Klocke
- Mara Egerer
Institutions
- Vivantes Klinikum (DE)
- University College London (GB)
- Charité - Universitätsmedizin Berlin (DE)
- Leipzig University (DE)
Publication Details
- Journal
- Liver International
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1111/liv.70121
- Citations
- 6
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 7.93